Cullinan CMO sells shares to cover RSU taxes

Cullinan Therapeutics Chief Medical Officer trades shares to cover taxes.

(Neutral)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cullinan Therapeutics Chief Medical Officer trades shares to cover taxes. Jeffrey Alan Jones reported an open-market sale of 4,982 shares of common stock at $13.62 per share on February 20, 2026, to cover personal income tax obligations upon vesting of restricted stock units, and now holds 164,550 shares directly.

Insider Trade Summary

Net Seller: 4,982 shares

Net Sell 1 txn

Insider Jones Jeffrey Alan

Role Chief Medical Officer

Sold 4,982 shs ($68K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,982	$13.62	$68K

Holdings After Transaction: Common Stock — 164,550 shares (Direct)

Footnotes (1)

F1. Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cullinan Therapeutics (CGEM) report for Jeffrey Alan Jones?

Cullinan Therapeutics reported that Chief Medical Officer Jeffrey Alan Jones sold 4,982 shares of common stock. The transaction occurred on February 20, 2026, as an open-market sale linked to tax obligations on vesting restricted stock units.

What was the sale price in the latest CGEM insider transaction?

Jeffrey Alan Jones sold Cullinan Therapeutics common stock at $13.62 per share. This price applied to 4,982 shares in an open-market transaction executed on February 20, 2026, connected to personal income tax obligations from restricted stock unit vesting.

How many Cullinan Therapeutics (CGEM) shares does Jeffrey Alan Jones hold after the sale?

After the reported transaction, Jeffrey Alan Jones directly holds 164,550 shares of Cullinan Therapeutics common stock. This figure reflects his ownership following the 4,982-share open-market sale on February 20, 2026, related to tax obligations on restricted stock unit vesting.

Why did Jeffrey Alan Jones sell Cullinan Therapeutics (CGEM) shares?

The filing states the shares were sold to cover personal income tax obligations upon vesting of restricted stock units. This indicates the sale was tied to compensation-related tax requirements, rather than a discretionary portfolio trade unrelated to equity award vesting.

What transaction code was used in the latest CGEM Form 4 filing?

The transaction used code “S,” indicating a sale in an open market or private transaction. The Form 4 further describes it as an open-market sale of 4,982 Cullinan Therapeutics common shares tied to tax obligations from restricted stock unit vesting.

Is the Jeffrey Alan Jones CGEM transaction categorized as a buy or sell?

The transaction is categorized as a sell. The Form 4 labels it as an open-market sale of 4,982 common shares, with transaction code “S” and a footnote describing it as a sale to cover income taxes on restricted stock unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/23/2026 - 05:00 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Jeffrey Alan

(Last)

(First)

(Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/20/2026		S⁽¹⁾		4,982	D	$13.62	164,550	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR